Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Fortrea Holdings Inc.
Fortrea Holdings Inc. News
May 12, 2025 - businesswire.com
Securities Fraud Investigation Into Fortrea Holdings Inc. (FTRE) Continues – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
May 12, 2025 - businesswire.com
Fortrea Holdings Inc. (FTRE) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Fortrea Holdings Inc. Quantitative Score
About Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Fortrea Holdings Inc. Earnings & Revenue
Fortrea Holdings Inc. Financials
Table Compare
Compare FTRE metrics with: | |||
|---|---|---|---|
Earnings & Growth | FTRE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | FTRE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | FTRE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | FTRE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Fortrea Holdings Inc. Income
Fortrea Holdings Inc. Balance Sheet
Fortrea Holdings Inc. Cash Flow
Fortrea Holdings Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Fortrea Holdings Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Fortrea Holdings Inc. Executives
| Name | Role |
|---|---|
| Ms. Jill McConnell | Chief Financial Officer |
| Mr. Mark A. Morais | Chief Operating Officer & President of Clinical Services |
| Dr. Oren J. Cohen M.D. | Chief Medical Officer & President of Clinical Pharmacology |
| Dr. John J. Doyle M.D. | Chief Scientific Officer & President of Consulting Services |
| Mr. Robert Parks | Chief Accounting Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Jill McConnell | Chief Financial Officer | Female | 1975 | 521.36K |
| Mr. Mark A. Morais | Chief Operating Officer & President of Clinical Services | Male | 1977 | 517.09K |
| Dr. Oren J. Cohen M.D. | Chief Medical Officer & President of Clinical Pharmacology | 1961 | -- | |
| Dr. John J. Doyle M.D. | Chief Scientific Officer & President of Consulting Services | -- | ||
| Mr. Robert Parks | Chief Accounting Officer | Male | -- |
Fortrea Holdings Inc. Insider Trades
| Date | 14 May |
| Name | Smith David Ross |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 7282 |
| Date | 14 May |
| Name | Smith David Ross |
| Role | Director |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 2185 |
| Date | 14 May |
| Name | Smith David Ross |
| Role | Director |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 7282 |
| Date | 14 May |
| Name | Pesicka Edward A |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 7282 |
| Date | 14 May |
| Name | Pesicka Edward A |
| Role | Director |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 7282 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 14 May | Smith David Ross | Director | Acquired | M-Exempt | 7282 |
| 14 May | Smith David Ross | Director | Disposed | F-InKind | 2185 |
| 14 May | Smith David Ross | Director | Disposed | M-Exempt | 7282 |
| 14 May | Pesicka Edward A | Director | Acquired | M-Exempt | 7282 |
| 14 May | Pesicka Edward A | Director | Disposed | M-Exempt | 7282 |